The trajectory of Viagra, initially marketed by copyright, presents a intricate case study for stakeholders considering the drug sector. Despite its initial success and creation of billions in earnings , the exclusivity end has opened the floodgates for competing medications, significantly diminishing profit opportunities. This shift raises questio